Avience Biomedicals Limited IPO

Incorporated in 2019 and headquartered in Noida, Uttar Pradesh, Avience Biomedicals Limited manufactures and markets a wide range of diagnostic and healthcare products under its proprietary "Avienbio" brand. The company's portfolio includes rapid diagnostic test kits, molecular diagnostic products, culture media, biochemistry reagents, electrolyte analysers, laboratory plasticware, microbiology products, oxygen concentrators and other healthcare consumables.

The company serves pathology laboratories, hospitals, healthcare facilities, research institutions, government agencies and distributors across India and select international markets. In addition to manufacturing its own products, Avience Biomedicals acts as an authorized channel partner for leading diagnostic equipment manufacturers, supplying imported diagnostic analysers and related consumables. As of January 31, 2026, the company had 75 employees including contract workforce.

The IPO is a book-built NSE SME issue comprising a fresh issue of 14,53,800 equity shares aggregating up to Rs 30.24 crore. The price band has been fixed at Rs 196-208 per share. The IPO opens on June 18, 2026 and closes on June 22, 2026, with listing scheduled on NSE Emerge on June 25, 2026.

The company reported revenue of Rs 45.24 crore and net profit of Rs 7.23 crore in FY2025, compared to revenue of Rs 23.96 crore and net profit of Rs 2.14 crore in FY2024. At the upper price band, the issue is valued at approximately 10.91x FY2025 earnings. Key strengths include a diversified diagnostics product portfolio, growing healthcare market presence, strong profitability, improving return ratios and an established manufacturing capability. Key risks include dependence on the healthcare diagnostics sector, competition from larger diagnostic companies, regulatory compliance requirements and customer concentration risks.